Position of the Transparency Council – Dezacor (deflazacort)
At its meeting on 23 December 2024, the Transparency Council adopted position No. 156/2024 on the appropriateness of issuing approvals for reimbursement of the drug Dezacor (deflazacort) for the indication Duchenne muscular dystrophy